Second phase of clinical trials of Cuban Soberana 02 vaccine candidate kicks off
After having approved phase 2 of clinical trials of its second vaccine candidate to prevent COVID-19, called Soberana 02, Cuba began vaccinating volunteers, Havana’s Finlay Institute reported this Tuesday. “This week the vaccination process of the Phase II Clinical Trial of vaccine #Soberana02 began. Everything has gone normally and complying with good practices,” the scientific center dedicated to research and vaccine production reported on Twitter. https://twitter.com/FinlayInstituto/status/1341466351437799425?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1341466351437799425%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Foncubanews.com%2Fcuba%2Fcuba-inicia-segunda-fase-de-ensayos-clinicos-de-su-candidato-vacunal-soberana-02%2F In this Cuban vaccine candidate, the virus antigen and tetanus toxoid are combined, as the director general of the Finlay Vaccine Institute, Vicente Vérez, recently explained. Phase 2 should involve about a hundred people, which will increase to between 300 and 600 in a phase II-B. Phase 3―more complex to develop on the island due to the low incidence of the disease―should include an even greater number of volunteers. Vérez described this future conjugate vaccine as “innovative” because, he assured, its formulation is unprecedented among all those currently being developed in the world to face SARS-CoV-2. On December 17, after preliminary positive results of phase I, “Soberana 02" received authorization from the island’s Center for State Control of Medicines, Equipment and Medical Devices to advance to phase II of clinical trials, which is why...